Form 4: Beam Therapeutics Executive Sells Shares for Tax Withholding

Bethany J. Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics Inc., executed a Rule 10b5-1 plan sale of 3,242 shares to cover tax obligations upon vesting of restricted stock units.

Summary

• Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 3,242 shares of common stock on April 1, 2026.
• The sale was part of a pre-arranged, non-discretionary transaction under a Rule 10b5-1 trading plan adopted on August 9, 2024.
• The purpose of the sale was to cover tax withholding obligations arising from the vesting of restricted stock units.
• These restricted stock units were granted under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on various dates between March 31, 2022, and March 31, 2025.
• Following the transaction, Cavanagh beneficially owns 51,171 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a standard, pre-planned transaction for tax withholding purposes and does not indicate a change in the executive's confidence in the company.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating pre-planned and orderly execution to avoid insider trading concerns.
• The sale was for tax withholding purposes, a standard and expected event upon the vesting of equity awards.
• The reporting person continues to hold a significant number of shares (51,171) after the transaction.

Negatives

• A portion of the executive's equity award was sold, reducing their direct holdings.

Risks

• The sale of shares by a key executive could be misinterpreted by the market, although it is for tax purposes.
• The vesting of restricted stock units and subsequent tax withholding obligations highlight the cost of equity compensation.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and often reflect planned sales for tax purposes, especially following equity award vesting. The use of a Rule 10b5-1 plan is a common and accepted practice to manage such transactions while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: The sale is pre-planned and for tax purposes, so it is unlikely to have a significant negative impact on the share price. The continued beneficial ownership by the executive suggests ongoing commitment.

Key Dates

Keywords

Form 4, SEC Filing, Beam Therapeutics, BEAM, Insider Transaction, Stock Sale, Tax Withholding, Rule 10b5-1, Restricted Stock Units, Equity Compensation, Bethany J. Cavanagh